Sinolink Securities issued a research report on Changchun High-tech, stating that the company announced a revised restructuring plan. The transaction objects, transaction targets, and supporting funds raised for this transaction have not changed, so the adjustment of this transaction plan does not constitute a major adjustment. If this reorganization can be successfully implemented, the proportion of shares held by listed companies in Kinsey Pharmaceuticals will increase from 70% to 99.5%, which is also expected to have a good incentive effect and increase the certainty of future growth of Kinsey Pharmaceuticals. Regardless of the impact of asset restructuring on the company's performance, the research report is optimistic about the growth prospects of the growth hormone business. It is estimated that the company's net profit attributable to shareholders from 2019 to 2021 will be 1.36 billion, 1.81 billion, and 2.36 billion yuan respectively, an increase of 35%, 33%, and 30% respectively. Maintain "Buy" rating.